News - TP53 mutation - LARVOL VERI

Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression. (PubMed, Cureus)

These findings underscore the need for targeted interventions, such as epigenetic therapies, metabolic reprogramming, and robust tobacco control policies, to mitigate the global burden of tobacco-related diseases. By providing a unified framework for understanding tobacco's molecular impact, this research advocates for precision medicine and public health strategies to address the pervasive effects of tobacco on human health.

2 days ago

Review • Journal • PARP Biomarker • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATR (Ataxia telangiectasia and Rad3-related protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MTHFR (Methylenetetrahydrofolate Reductase) • SOX2 • CASP3 (Caspase 3) • POU5F1 (POU Class 5 Homeobox 1) • CASP9 (Caspase 9) • HDAC1 (Histone Deacetylase 1) • YBX1 (Y-Box Binding Protein 1) • NANOG (Nanog Homeobox) • DRD2 (Dopamine Receptor D2) • SUV39H1 (SUV39H1 Histone Lysine Methyltransferase) • TCF4 (Transcription Factor 4) • COMT (Catechol-O-Methyltransferase)

TP53 mutation

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=26, Active, not recruiting, University of Chicago | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

2 days ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53)

TP53 mutation

Venclexta (venetoclax) • decitabine

NCI 10211: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)

P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

2 days ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)

HER-2 positive • TP53 mutation • MSI-H/dMMR

FoundationOne® CDx

irinotecan • berzosertib (M6620)

Decoding the metabolic-immune axis for novel therapeutics in bladder cancer. (PubMed, Biochim Biophys Acta Rev Cancer)

In particular, the dynamic interplay between tumor cell metabolic reprogramming and the immune suppressive tumor microenvironment, collectively termed the "metabolic-immune axis", constitutes a major challenge underlying drug resistance. This review summarizes how this axis, through mechanisms such as enhanced glycolysis and abnormal amino acid/lipid metabolism, influences bladder cancer progression and treatment responsiveness, thereby establishing a theoretical framework for future research directions.

2 days ago

Review • Journal • IO biomarker

TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDH1 (Cadherin 1) • RASSF1 (Ras Association Domain Family Member 1)

TP53 mutation • FGFR3 mutation

Benzo[a]pyrene promotes gastric cancer progression via activation of the Correa cascade through modulation of the STAT3-TP53-MMP9 molecular axis. (PubMed, Ecotoxicol Environ Saf)

In summary, this study identifies STAT3, TP53, and MMP9 as central mediators of BaP-induced progression along the Correa cascade via a synergistic regulatory network. These findings provide new insights into environmental gastric carcinogenesis and highlight potential therapeutic strategies, including dual STAT3/MDM2 inhibition or MMP9 blockade.

2 days ago

Journal

TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • PIAS4 (Protein Inhibitor Of Activated STAT 4)

TP53 mutation

IFN-α in Relapse Prevention. (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Peking University People's Hospital

2 days ago

New P2 trial

TP53 (Tumor protein P53)

TP53 mutation

Clonal haematopoiesis and risk of incident rheumatoid arthritis: results from the UK biobank. (PubMed, Clin Exp Rheumatol)

Common CHIP mutations, including TET2, TP53, and SF3B1 mutations, were not associated with risk of incident RA when restricted to those with most complete general outpatient and hospital record follow-up in the UK Biobank.

3 days ago

Journal

TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

TP53 mutation • TET2 mutation • SF3B1 mutation

Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy. (PubMed, Hematol Oncol)

Fifty-three patients received treatment after venetoclax: 29/53 (54.7%) received inhibitors (13 cBTKi, 11 idelalisib, 2 BCL2i, 3 non-covalent BTKi), 19/53 (35.8%) received chemoimmunotherapy (CT: 16 intensive, 3 palliative), 5/53 (9.4%) received hematopoietic stem cell transplantation (HSCT). Despite its limitations, this real-world study provides additional insights into double-exposed patients, who still pose a clinical challenge, demonstrating the superior efficacy of inhibitors over alternative treatment options. Enrollment in clinical trial and treatments with novel molecules, if available, may help address this unmet clinical need.

3 days ago

Clinical data • Journal • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)

TP53 mutation • TP53 mutation + Chr del(17p)

Venclexta (venetoclax) • Zydelig (idelalisib)

APOs as promising prognostic biomarkers: correlation with tumor-infiltrating leukocytes in endometrial cancer. (PubMed, Front Immunol)

Furthermore, APOE was identified to promote the cell migration by scratch assay. The expression of APOs may be a promising prognostic biomarker and is associated with immune invasion as a potential target for endometrial cancer.

3 days ago

Journal

ER (Estrogen receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • POLD1 (DNA Polymerase Delta 1) • APOE (Apolipoprotein E)

TP53 mutation

Uterine tumors resembling ovarian sex cord tumors: rare case report and literature review. (PubMed, Front Oncol)

At 20 months the patient is disease-free with regular menses and intact fertility. We review diagnostic clues, differential diagnoses, molecular taxonomy and fertility-sparing strategies, underscoring the value of comprehensive genomic profiling for accurate classification and prognostication of this uncommon uterine tumor.

3 days ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • NCAM1 (Neural cell adhesion molecule 1) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SYP (Synaptophysin) • NCOA2 (Nuclear Receptor Coactivator 2)

TP53 mutation • BRCA2 mutation • BRCA1 mutation

Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)

P1/2, N=3, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

3 days ago

New P1/2 trial

TP53 (Tumor protein P53) • CD19 (CD19 Molecule)

TP53 mutation

cyclophosphamide • fludarabine IV

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)

P1, N=16, Not yet recruiting, National Cancer Institute (NCI)

3 days ago

New P1 trial

TP53 (Tumor protein P53)

TP53 mutation

cisplatin • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)